Cinarizine - instructions for use, dose, side effects, contraindications

1 tablet contains: active substance: cinnarizine - 0.025 g, auxiliary matter: potato starch - 0.0178 g, lactose (milk sugar) - 0.102 g, povidone medium molecular - 0.0030 g, silicon dioxide colloid (aerosil) - 0.0007 g, magnesium stearate - 0.0015 g.

Description:

white or white tablets with a creamy hue, flat cylindrical with a bevel, marked "R" on one side or without it.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

Selective blocker "slow" calcium channels, reduces the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, reduces the tone of smooth muscle arterioles. Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Effective in patients with lateral cerebral insufficiency, initial cerebral arteriosclerosis and chronic cerebrovascular diseases with post-stroke focal symptoms. In patients with impaired peripheral circulation improves blood supply to organs and tissues (including myocardium), enhances postischemic vasodilation. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood. Increases muscle resistance to hypoxia.

Pharmacokinetics:

The drug is absorbed in the stomach and intestines. The maximum concentration in the blood plasma after oral administration after 1-3 hours. The connection of cinnarizine with plasma proteins is 91%. Completely metabolized in the liver (via dealkylation). The half-life is 4 hours. It is excreted in the form of metabolites: 1/3 - kidney and 2/3 - with fecal masses - intestine.

Indications:

symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration of attention);
vestibular disorders (including Meniere's disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin);
prevention of kinetosis ("road sickness" - sea and air sickness);
migraine (prevention of seizures);
violations of peripheral circulation: Raynaud's disease, "intermittent" lameness, acrocyanosis, trophic disorders (including trophic and varicose ulcers).

Contraindications:

Hypersensitivity, pregnancy, lactation.

Lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

Children under 5 years.

Carefully:

Parkinson's disease.

Pregnancy and lactation:

Contraindicated use of the drug during pregnancy. At the time of taking the drug, breast-feeding should be discontinued.

Dosing and Administration:

Inside, after eating.

Adults:

With insufficiency of cerebral circulation, with vestibular disorders, for prevention of migraine, 25 mg three times a day;
At violations of peripheral circulation - 50-75 mg three times a day;
For the prevention of "road disease" - 25 mg for half an hour before the road (if necessary, repeated intake of 25 mg after 6 hours).

The maximum daily dose of the drug should not exceed 225 mg (9 tablets) per day.

Children over 5 years - 1/2 dose, recommended for adults, for all indications.

The duration of the course of treatment is from several weeks to several months. To achieve the optimal therapeutic effect, the drug should be taken continuously.

With high sensitivity to the drug, treatment starts with 1/2 dose, increasing it gradually.

Side effects:

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (limb tremor and increased muscle tone, hypokinesia |), depression.

From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: sweating, development of lupus-like syndrome, red flat lichen (extremely rare), skin rash.

Other: allergic reactions, lowering blood pressure, increasing body weight.

Overdose:

Symptoms: vomiting, drowsiness, tremor, lowering of blood pressure, coma.

Treatment: there is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.

Interaction:

Strengthens the inhibitory effect on the central nervous system of ethanol, sedatives, tricyclic antidepressants.

Special instructions:

Patients suffering from Parkinson's disease, the drug should be prescribed only when the benefits of treatment outweighs the possible worsening of the underlying disease. In connection with the antihistamine effect, the drug should be discontinued 4 days before the allergic skin test.

The drug can affect the result in the anti-doping control of athletes (false positive result).

Patients with intolerance to lactose, it should be noted that it is part of the drug.

With prolonged use, it is recommended to conduct a control laboratory examination of the liver, kidneys, peripheral blood.

During the treatment with the drug should refrain from drinking alcohol.

Effect on the ability to drive transp. cf. and fur:

It is possible to develop drowsiness, especially at the beginning of treatment, therefore, care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

Form release / dosage:

Tablets 25 mg.

Packaging:

For 10, 14, 50 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil.

5, 10 contour cell packs of 10 tablets or 4 contour packs of 14 tablets with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry place protected from light. Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002351 / 01

Date of registration:02.10.2009

The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia

Manufacturer: & nbsp

UPDATE, PFC CJSC Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)